➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Harvard Business School
AstraZeneca
McKinsey

Last Updated: May 8, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Cabotegravir

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Cabotegravir?

Cabotegravir is an investigational drug.

There have been 24 clinical trials for Cabotegravir. The most recent clinical trial was a Phase 1 trial, which was initiated on October 15th 2020.

The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are ViiV Healthcare, National Institute of Allergy and Infectious Diseases (NIAID), and GlaxoSmithKline.

There are one hundred and four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Cabotegravir
TitleSponsorPhase
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and PostpartumEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 4
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and PostpartumGilead SciencesPhase 4

See all Cabotegravir clinical trials

Clinical Trial Summary for Cabotegravir

Top disease conditions for Cabotegravir
Top clinical trial sponsors for Cabotegravir

See all Cabotegravir clinical trials

US Patents for Cabotegravir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cabotegravir   Get Started for $10 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Get Started for $10
Cabotegravir   Get Started for $10 C17-aryl substituted betulinic acid analogs ViiV HEALTHCARE UK (NO.5) LIMITED (Brentford, Middlesex, GB)   Get Started for $10
Cabotegravir   Get Started for $10 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits ELIAN LLC (Monrovia, CA)   Get Started for $10
Cabotegravir   Get Started for $10 Compounds and combinations for the treatment of HIV Gilead Sciences, Inc. (Foster City, CA)   Get Started for $10
Cabotegravir   Get Started for $10 Compounds and compositions for treating HIV with derivatives of Betulin GLAXOSMITHKLINE LLC (Wilmington, New Castle, DE)   Get Started for $10
Cabotegravir   Get Started for $10 Therapeutic compounds Gilead Sciences, Inc. (Foster City, CA)   Get Started for $10
Cabotegravir   Get Started for $10 Long acting pharmaceutical compositions GlaxoSmithKline Intellectual Property (No. 2) Limited (Brentford, Middlesex, GB)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cabotegravir

Drugname Country Document Number Estimated Expiration Related US Patent
Cabotegravir Australia AU2012345732 2031-11-30   Get Started for $10
Cabotegravir Australia AU2016244212 2031-11-30   Get Started for $10
Cabotegravir Brazil BR112014013224 2031-11-30   Get Started for $10
Cabotegravir Canada CA2856722 2031-11-30   Get Started for $10
Cabotegravir China CN104185420 2031-11-30   Get Started for $10
Cabotegravir China CN107898790 2031-11-30   Get Started for $10
Cabotegravir European Patent Office EP2785184 2031-11-30   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Dow
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.